证券代码：301258 证券简称：富士莱 公告编号：2025-028 苏州富士莱医药股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 特别提示： 1.本次股东大会不存在否决议案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 （一）会议召开的时间 1、现场会议时间：2025 年 5 月 16 日下午 14:30。 2、网络投票时间：2025 年 5 月 16 日 （1）通过深圳证券交易所交易系统进行网络投票的时间为： 2025 年 5 月 16 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00； （2）通过深圳证券交易所互联网投票系统进行网络投票的时间为 2025 年 5 月 16 日 9:15-15:00。 （二）现场会议召开地点：江苏省常熟市新材料产业园海旺路 16 号 （三）股权登记日：2025 年 5 月 12 日（星期一） （五）股东大会的召集人：公司董事会 （六）会议主持人：董事长钱祥云先生 （七）会议的召集、召开与表决程序符合《公司法》《上市 ...

上海兰迪（苏州）律师事务所 法律意见书 上海兰迪（苏州）律师事务所 2024 年年度股东大会的 法律意见书 地址：苏州市姑苏区人民路 3110 号国发大厦南楼 907 电话：0512-67872033 关于苏州富士莱医药股份有限公司 上海兰迪（苏州）律师事务所 法律意见书 上海兰迪（苏州）律师事务所 关于苏州富士莱医药股份有限公 司 2024 年年度股东大会的 法律意见书 致：苏州富士莱医药股份有限公司 上海兰迪（苏州）律师事务所（以下简称"本所"）接受苏州富士莱医药股份有 限公司（以下简称"公司"）的委托，就贵公司召开的 2024 年年度股东大会（以下 简称"本次股东大会"）进行见证并就相关事宜出具本法律意见书。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以 下简称"《股东大会规则》"）、《深圳证券交易所上市公司股东大会网络投票实施 细则》以及《苏州富士莱医药股份有限公司章程》（以下简称"《公司章程》"）等 规定，就本次股东大会的召集和召开程序、召集人资格和出席会议人员资格、会议表 决程序和表决结果等相关事 ...

Core Viewpoint - The company held an online performance briefing for 2024 and Q1 2025, addressing concerns about declining revenue and net profit due to increased competition and price drops in the market for lipoic acid products [1][2]. Revenue and Profit Decline - The company reported a revenue of 429.468 million yuan for 2024, a decrease of 12.23% year-on-year, and a net profit attributable to shareholders of 16.4061 million yuan, down 85.38% year-on-year [3]. Product Performance - The company noted a stable market demand for lipoic acid series products in 2024, with a 21.35% year-on-year increase in the shipment volume of granular lipoic acid, despite prices not showing significant recovery [3]. New Product Development and Business Expansion - The company has received approval for the active pharmaceutical ingredient (API) of Apatinib and plans to focus on specialty APIs, CMO/CDMO expansion, and new product development [4]. - The company is investing in R&D for specialty APIs and has initiated five API projects in 2024, with some projects already completing initial testing [4]. Other Key Points - The construction of the Shandong branch is expected to take 30 months, with completion aimed for June 2026, and will include multiple production lines for specialty APIs and intermediates [5]. - Approximately 9% of the company's revenue in 2024 is expected to come from direct exports to the U.S., with close monitoring of tariff policy changes [5].

Core Insights - Fujilai (SZ301258) reported a significant decline in financial performance for the year 2024, with total revenue of 429.47 million yuan, a decrease of 12.23% compared to 2023 [1][2] - The net profit attributable to shareholders dropped to 16.41 million yuan, reflecting an 85.38% decline year-on-year [1][2] - The company experienced a substantial loss in net profit after deducting non-recurring items, amounting to -8.92 million yuan, a decrease of 109.96% [1][2] Financial Performance - Total revenue for 2024 was 429,468,011.82 yuan, down from 489,292,586.96 yuan in 2023, marking a 12.23% decline [2][3] - Net profit attributable to shareholders was 16,406,148.23 yuan, compared to 112,181,787.31 yuan in 2023, a decrease of 85.38% [2][3] - The net profit after deducting non-recurring items was -8,924,873.45 yuan, down from 89,606,898.67 yuan in 2023, indicating a decline of 109.96% [2][3] - Operating cash flow net amount was 47,068,013.45 yuan, a decrease of 50.33% from 94,768,588.39 yuan in 2023 [2][3] Revenue Breakdown - Revenue from external sales was 211.23 million yuan, a decline of 31.39%, while domestic sales revenue increased by 20.31% to 218.24 million yuan [2][3] - Sulfuric acid series revenue was 276.48 million yuan, down 26.25% year-on-year [2][3] - The revenue from the raw material drug, Arixib, surged by 835.06% to 62.98 million yuan [2][3] Product and Business Segmentation - The pharmaceutical main business accounted for 99.19% of total revenue, with a total of 426,006,805.49 yuan, down 11.82% from the previous year [3] - The sulfuric acid series products contributed 64.38% of total revenue, while the phosphatidylcholine series and the dipeptide series accounted for 9.57% and 10.58%, respectively [3] - Other business segments saw a significant decline of 44.10%, contributing only 3.46 million yuan to total revenue [3] Company Leadership - The chairman of Fujilai is Qian Xiangyun, who has been in the role since August 2008 and has a background in various positions within the company and local government [4] - Qian Xiangyun's compensation has varied over the years, with a reported salary of 82.40 million yuan in 2024 [5][6]

Market Overview - The Shanghai Composite Index closed at 3299.76 points, above the annual line, with a change of 0.25% [1] - The total trading volume of A-shares reached 1,121.207 billion yuan [1] Stocks Breaking Annual Line - A total of 106 A-shares have broken above the annual line today [1] - Notable stocks with significant deviation rates include: - Youbuxun: 17.49% deviation, closing price at 15.18 yuan, with a daily increase of 20.00% and turnover rate of 6.57% [1] - Fujilai: 14.53% deviation, closing price at 29.09 yuan, with a daily increase of 20.01% and turnover rate of 30.40% [1] - Chongqing Construction: 8.33% deviation, closing price at 3.01 yuan, with a daily increase of 9.85% and turnover rate of 2.93% [1] Additional Stocks with Minor Deviations - Jiangxi Copper, Meirya, and Laimu Co. have just crossed the annual line with smaller deviation rates [1] - Other stocks with notable performance include: - Changjiang Investment: 7.98% deviation, closing price at 8.01 yuan, with a daily increase of 10.03% [1] - Qingtang City: 7.70% deviation, closing price at 3.78 yuan, with a daily increase of 9.88% [1] - Shenchuan A: 7.45% deviation, closing price at 6.75 yuan, with a daily increase of 9.93% [1] Summary of Stocks with Deviation Rates - A detailed table lists various stocks, their daily change percentages, turnover rates, annual line prices, latest prices, and deviation rates, highlighting the performance of stocks like: - Dongjiang Environmental: 3.70% deviation, closing price at 4.28 yuan, with a daily increase of 10.03% [1] - Feinan Resources: 3.56% deviation, closing price at 19.88 yuan, with a daily increase of 3.92% [1] - The table provides a comprehensive view of the market dynamics and stock performances on the day [2]

医药板块持续走高 众生药业等多股涨停 智通财经4月22日电，午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨 停，百利天恒、诺诚健华、新诺威、百济神州创历史新高，复旦张江、上海谊众、信立泰、热景生物等 涨幅靠前。消息面上，4月25日至4月30日，美国癌症研究协会（AACR）年会将在芝加哥召开。作为全 球规模最大的癌症研究会议之一，AACR年会一直是癌症领域最新研究成果的重要展示平台。 ...

Market Overview - As of 10:29 AM today, the Shanghai Composite Index is at 3298.26 points, below the six-month moving average, with a change of 0.21% [1] - The total trading volume of A-shares today is 534.203 billion yuan [1] Stocks Performance - A total of 107 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates including: - Hongxing Co., Ltd. with a deviation rate of 8.41% - Yudai Development with a deviation rate of 7.54% - Cuiwei Co., Ltd. with a deviation rate of 7.02% [1] - Other stocks that have just crossed the six-month moving average with smaller deviation rates include: - Bull Group - Inner Mongolia Xinhua - New Energy Group [1] Top Stocks by Deviation Rate - The following stocks have the highest deviation rates from the six-month moving average: - Hongxing Co., Ltd. (9.98% increase, 6.07% turnover rate, latest price 18.19 yuan) - Yudai Development (9.56% increase, 10.62% turnover rate, latest price 4.70 yuan) - Cuiwei Co., Ltd. (9.98% increase, 6.10% turnover rate, latest price 9.15 yuan) [1] Additional Notable Stocks - Other notable stocks with significant performance include: - Hai Xin Food (10.00% increase, 9.46% turnover rate, latest price 4.62 yuan) - Yongtai Transportation (6.27% increase, 9.71% turnover rate, latest price 22.71 yuan) - Shengyibao (9.98% increase, 9.68% turnover rate, latest price 19.84 yuan) [1]

富士莱：一季度净利润同比增长314% 智通财经4月21日电，富士莱(301258.SZ)发布一季报，营业收入1.13亿元，同比增长17.44%；归属于上 市公司股东的净利润为2393.68万元，同比增长313.65%。净利润增加主要系本期投资收益和公允价值变 动收益增加较多所致。 ...

苏州富士莱医药股份有限公司 2024 年年度财务报告 苏州富士莱医药股份有限公司 2024 年度财务报告 2025 年 4 月 1 苏州富士莱医药股份有限公司 2024 年年度财务报告 财务报告 一、审计报告 | 审计意见类型 | 标准的无保留意见 | | --- | --- | | 审计报告签署日期 | 2025 年 04 月 18 日 | | 审计机构名称 | 容诚会计师事务所（特殊普通合伙） | | 审计报告文号 | 容诚审字[2025]230Z0309 号 | | 注册会计师姓名 | 陈雪、徐远、孙能康 | 审计报告正文 苏州富士莱医药股份有限公司全体股东： 一、审计意见 我们审计了苏州富士莱医药股份有限公司（以下简称富士莱公司）财务报表，包括 2024 年 12 月 31 日的合并及母 公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及相 关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了富士莱公司 2024 年 12 月 31 日的合并及母公司财务状况以及 2024 年度的合并及母公司经营成果和现 ...

苏州富士莱医药股份有限公司 2024年度非经营性资金占用及其他关联资金往来情况汇总表 公司法定代表人：钱祥云 主管会计工作的负责人：卞爱进 会计机构负责人：卞爱进 附件： | 编制单位：苏州富士莱医药股份有限公司 | | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司 | 上市公司核算的 | 2024年初占用资 | 2024年度占用累 计发生金额(不含 | 2024年度占用资 | 2024年度偿还累 | 2024年末占用资 | | 占用形成原因 | 占用性质 | | | | 的关联关系 | 会计科目 | 金余额 | 利息) | 金的利息(如有) | 计发生金额 | 金余额 | | | | | 控股股东、实际控制人及 其附属企业 | / | / | / | — | — | — | | — | — | / | / | | 小计 | | | | — | — | — | | — | — | | | | 前 ...